Effect of Pecha Kucha-Based Education on Symptom Management and Quality of Life in Patients Receiving Chemotherapy

August 19, 2026 updated by: Asiye TAN, Istanbul Aydın University

The Effect of Education Provided Using the PechaKucha Method on Symptom Management and Quality of Life in Patients Receiving Chemotherapy

This randomized controlled study aims to evaluate the effect of education delivered using the PechaKucha method on symptom management and quality of life in patients receiving chemotherapy. Participants will be randomly assigned to either an intervention group or a control group.

Participants in the intervention group will receive individual education on symptom management during chemotherapy using the PechaKucha method. The education will be delivered as a video presentation consisting of 20 visual slides and lasting 6 minutes and 40 seconds. Participants in the control group will receive routine/standard patient education.

Symptom severity and quality of life will be assessed before the education and one week after the intervention using the Edmonton Symptom Assessment System (ESAS) and the EQ-5D. The study will compare changes in symptom severity and quality of life between the intervention and control groups to determine whether PechaKucha-based education is effective in supporting symptom management and quality of life among patients receiving chemotherapy.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This randomized controlled experimental study is designed to evaluate the effect of education delivered using the PechaKucha method on symptom management and quality of life in patients receiving chemotherapy. The study is being conducted in the Chemotherapy Unit of Health Sciences University Kanuni Sultan Süleyman Training and Research Hospital, with participant enrollment beginning in June 2026.

Participants will be assigned to an intervention group or a control group. Participants in the intervention group will receive individual education on "Symptom Management During Chemotherapy," delivered by the researchers using the PechaKucha method. The educational intervention will be presented as a video consisting of 20 visual slides with a total duration of 6 minutes and 40 seconds. The educational content addresses common chemotherapy-related symptoms and problems, including pain, nausea, anemia, fatigue, diarrhea, constipation, risk of infection, anxiety, depression, mucositis, and alopecia. Participants in the control group will receive routine/standard patient education.

Data will be collected through face-to-face interviews. At baseline, participants in both groups will complete the Patient Information Form, the Edmonton Symptom Assessment System (ESAS), and the EQ-5D. One week after the intervention, the ESAS and EQ-5D will be administered again to participants in both groups. The Patient Information Form, which is used to obtain demographic and clinical information, will be administered only at baseline.

Between-group comparisons will be performed using the independent-samples t-test or Mann-Whitney U test, as appropriate. Within-group pretest-posttest comparisons will be performed using the paired-samples t-test or Wilcoxon signed-rank test, as appropriate. Statistical significance will be set at p < 0.05.

Before participation, individuals will receive written and verbal information about the study, and informed consent will be obtained from all participants.

Study Type

Interventional

Enrollment (Estimated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye), 34520
        • Recruiting
        • SBÜ Kanuni Sultan Süleyman E.A.H
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Zülfiye Tosun Öztürkçi, MSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Willing to participate in the study.
  • Currently receiving treatment in the chemotherapy unit.
  • Aged 18 years or older, willing to participate, and able to communicate effectively.

Exclusion Criteria:

  • Being under 18 years of age.
  • Having cognitive or communication difficulties.
  • Having a visual or hearing impairment.
  • Being in an advanced or terminal stage of the disease.
  • Having a physical or psychological condition that prevents active participation in the educational process.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PechaKucha-Based Education Group
Participants in this arm will receive individual education on "Symptom Management During Chemotherapy" delivered by the researchers using the PechaKucha method. The education will be provided as a video presentation consisting of 20 visual slides with a total duration of 6 minutes and 40 seconds. The educational content covers pain, nausea, anemia, fatigue, diarrhea, constipation, risk of infection, anxiety, depression, mucositis, and alopecia.
Behavioral: PechaKucha-Based Symptom Management Education
The intervention consists of individual education on symptom management during chemotherapy delivered by the researchers using the PechaKucha method. The education is provided as a video presentation consisting of 20 visual slides, with each slide displayed for 20 seconds, for a total duration of 6 minutes and 40 seconds. The educational content addresses pain, nausea, anemia, fatigue, diarrhea, constipation, risk of infection, anxiety, depression, mucositis, and alopecia.
Active Comparator: Routine/Standard Education Group
Participants in this arm will receive routine/standard patient education provided as part of usual care in the chemotherapy unit. No PechaKucha-based education will be provided to participants in this group.
Behavioral: Routine/Standard Patient Education
Participants assigned to the control group will receive routine/standard patient education provided as part of usual care in the chemotherapy unit. This education does not include the PechaKucha-based symptom management education provided to the intervention group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Symptom Severity Assessed by the Edmonton Symptom Assessment System (ESAS)
Time Frame: Baseline (before the intervention) and one week after the intervention
The Edmonton Symptom Assessment System (ESAS) will be used to assess symptom severity in patients receiving chemotherapy. Participants rate the severity of each symptom on a numerical scale, with higher scores indicating greater symptom severity. The intervention group will receive symptom management education using the PechaKucha presentation format, whereas the control group will receive the same educational content using a conventional teaching method. Both groups will also receive a brochure summarizing the educational content. ESAS will be administered to both groups at baseline and one week after the intervention. Changes in symptom severity from baseline will be compared between the groups.
Baseline (before the intervention) and one week after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istanbul Aydın University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 3, 2026

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

August 13, 2026

First Submitted That Met QC Criteria

August 13, 2026

First Posted (Actual)

August 18, 2026

Study Record Updates

Last Update Posted (Actual)

August 20, 2026

Last Update Submitted That Met QC Criteria

August 19, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 240/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to share individual participant data (IPD).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe